Wolverine Asset Management LLC Invests $95,000 in Humacyte, Inc. (NASDAQ:HUMA)

Wolverine Asset Management LLC purchased a new position in shares of Humacyte, Inc. (NASDAQ:HUMA – Get Rating) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 13,150 shares of the company’s stock, valued at approximately $95,000.

Several other large investors have also recently added to or reduced their stakes in HUMA. Advisor Group Holdings Inc. acquired a new position in shares of Humacyte during the 3rd quarter worth $211,000. Citigroup Inc. acquired a new position in shares of Humacyte during the 3rd quarter worth $47,000. Geode Capital Management LLC acquired a new position in shares of Humacyte during the 3rd quarter worth $359,000. York Capital Management Global Advisors LLC acquired a new position in shares of Humacyte during the 3rd quarter worth $20,590,000. Finally, Morgan Stanley acquired a new position in shares of Humacyte during the 3rd quarter worth $840,000. 9.25% of the stock is owned by institutional investors and hedge funds.

Humacyte stock opened at $5.37 on Friday. The stock has a 50-day moving average price of $6.60 and a 200 day moving average price of $7.35. Humacyte, Inc. has a 52 week low of $4.37 and a 52 week high of $17.45. The company has a current ratio of 20.75, a quick ratio of 20.75 and a debt-to-equity ratio of 0.40.

Humacyte (NASDAQ:HUMA – Get Rating) last posted its quarterly earnings results on Tuesday, March 29th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.03). The business had revenue of $0.18 million during the quarter, compared to the consensus estimate of $0.26 million. As a group, equities research analysts expect that Humacyte, Inc. will post -0.85 earnings per share for the current year.

Several research firms have recently issued reports on HUMA. Zacks Investment Research downgraded Humacyte from a “buy” rating to a “hold” rating in a research note on Saturday, April 2nd. Piper Sandler dropped their price objective on Humacyte from $17.00 to $10.00 in a research report on Tuesday, March 29th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $13.65.

About Humacyte (Get Rating)

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs).

See Also